Multiple notable asset manager firms are altering their stakes in biotech company Cencora, Inc., with some reducing and others increasing their holdings. This comes amid significant activity from Cencora, including a $5 billion deal to take majority control of OneOncology, enlarging their footprint in cancer care. Evidently, there are high expectations for Cencora's growth as some analysts upgraded the firm's status, citing solid earnings prospects. A valuation opportunity is also suggested due to recent price pullbacks. However, the company isn't without competition, as it's noted that Cardinal Health could outperform them.
The past months have seen Cencora commit to notable expansion endeavors, such as the OneOncology acquisition and investment in U.S. drug distribution sector. Yet, these ventures have led to a temporary halt of stock buybacks, and a decrease in target price by Baird despite maintaining a 'Buy' rating. Refreshing financial models seem to be a focal point following Cencora's ambitious pursuits, seen in JPMorgan's raised price target. Nonetheless, the long-term EPS guide being lifted, maintaining an optimistic 2026 revenue growth outlook, and expected earnings growth are deemed favorable among investors and analysts.
Cencora COR News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:40:01 GMT - Rating 4 - Innovation 7 - Information 8 - Rumor -5
